Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 26 Mar 2026 | Rainer Becker Director | Urban Waste Water Treatment Directive (UWWTD) and its impact on the generic pharmaceutical industry | — |
| 26 Mar 2026 | Rainer Becker Director | Urban Waste Water Treatment Directive (UWWTD) and its impact on the generic pharmaceutical industry | SRC |
| 24 Mar 2026 | Nicolo Brignoli Cabinet member | Urban Wastewater Treatment Directive | — |
| 24 Mar 2026 | Nicolo Brignoli Cabinet member | Urban Wastewater Treatment Directive | SRC |
| 04 Mar 2026 | Olivér Várhelyi Commissioner | Exchange of views on regulatory issues | — |
| 04 Mar 2026 | Olivér Várhelyi Commissioner | Exchange of views on regulatory issues | SRC |
| 04 Mar 2026 | Katri Teedumäe Cabinet member | Exchange of views on regulatory issues | SRC |
| 04 Mar 2026 | Katri Teedumäe Cabinet member | Exchange of views on regulatory issues | — |
| 04 Mar 2026 | Karolina Tomaszewska-Boillot Cabinet member | Exchange of views on regulatory issues | — |
| 04 Mar 2026 | Karolina Tomaszewska-Boillot Cabinet member | Exchange of views on regulatory issues | SRC |
| 12 Nov 2025 | Michele Piergiovanni Cabinet member | Payment of fines in AT.39686 | — |
| 12 Nov 2025 | Michele Piergiovanni Cabinet member | Payment of fines in AT.39686 | SRC |
| 10 Jul 2025 | Ulla Schwager Head of Unit | Exchange of views on the pharmaceutical sector and on competition policy enforcement | SRC |
| 10 Jul 2025 | Michele Piergiovanni Acting Director | Exchange of views on the pharmaceutical sector and on competition policy enforcement | — |
| 10 Jul 2025 | Ulla Schwager Head of Unit | Exchange of views on the pharmaceutical sector and on competition policy enforcement | — |
| 10 Jul 2025 | Michele Piergiovanni Acting Director | Exchange of views on the pharmaceutical sector and on competition policy enforcement | SRC |
| 16 Jun 2021 | Maria Luisa Llano Cardenal Cabinet member | Supply chains for medicines | SRC |
| 16 Jun 2021 | Margaritis Schinas Vice-President | Supply chains for medicines | SRC |
| 16 Jun 2021 | Margaritis Schinas Vice-President | Supply chains for medicines | — |
| 20 Oct 2020 | Thierry Breton Commissioner | Production capacity of generic medicines in the EU | — |
| 20 Oct 2020 | Thierry Breton Commissioner | Production capacity of generic medicines in the EU | SRC |
| 28 Mar 2019 | Annika Nowak Cabinet member | Developments in the field of digital health | SRC |
| 28 Mar 2019 | Annika Nowak Cabinet member | Developments in the field of digital health | — |
Mission & Goals
Established in 1901, Teva is a global generic pharmaceuticals leader and one of the top 10 pharmaceutical companies in the world. Teva Pharmaceuticals is located across all major markets in Europe, operating across 28 manufacturing sites and employing over 19,000 people across its operations and commercial activities. Teva specializes in development, production and marketing of a wide range of generic and branded products. Teva also covers R&D and innovation, including on specific therapeutic areas such as CNS, pain, migraine and respiratory diseases.
EU Legislative Interests
Public Health and access to medicines, Industrial and IP Policies, Pricing and Reimbursement Policies, Pharmaceutical legislation, European external trade agenda, global health, sustainability and green policies.
Communication Activities
- Sustainability, Quality and Access to healthcare systems - digital health - Industrial policy Initiatives - Critical medicines alliance - Trade agreements - IP measures - Corporate social responsibility - Human medicines Regulatory Affairs
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Medicines for Europe - https://www.medicinesforeurope.com/ EFPIA - https://www.efpia.eu/about-us/membership/ Within CEFIC : --> EFCG (European Fine Chemicals Group - a CEFIC group) - https://efcg.cefic.org/ --> APIC (Active Pharmaceuticals Ingredients Committee) - https://www.apic.cefic.org/
Additional Information
Brussels office is composed of 4 people. 1 person spending 75% of their time on policy and advocacy activities and 3 person spending 50% of their time. 1 additional expert from the company spends 25% of her time on activities within the scope of the Register. Financial information includes relevant project costs, the relevant part of trade organisation fees together with our office facilities and other consulting fees.
Connected Legislation